Pernazene Oxy

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pernazene Oxy

Property Description
Active Ingredient Oxymetazoline hydrochloride
Form Nasal solution (spray or drops)
Pharmacological Class Nasal decongestant, Sympathomimetic
Common Use Relief of nasal stuffiness
Origin Synthetic, Imidazole derivative

Pernazene Oxy is the trade name for a medicinal product whose active substance is Oxymetazoline hydrochloride, a synthetic chemical compound used for the localized relief of nasal congestion. Pharmacologically, it is defined as a direct-acting sympathomimetic agent that functions as a potent alpha-adrenergic agonist, placing it within the functional category of nasal decongestants. This agent is widely clinically recognized for its ability to quickly reduce nasal mucosal swelling associated with conditions like the common cold or upper respiratory allergies.

Classification, Composition, and Form

Pernazene Oxy is typically formulated as an aqueous nasal solution intended for intranasal (topical) application, most commonly presented as a spray or in liquid drop form. The active ingredient is an imidazole derivative that is chemically synthesized. The solution consists of the active drug dissolved in a purified water base, which includes excipients such as buffering and stabilizing agents to ensure the product's quality and compatibility with the nasal mucosa. The compound exhibits strong alpha-adrenergic activity, indicating that its primary effect is achieved by directly targeting blood vessels rather than being systemically absorbed. This mechanism explains its localized and rapid action.

Primary Function and General Benefit

The core function of Oxymetazoline is to induce vasoconstriction, which is the physical narrowing of the small blood vessels within the nasal lining. This action is achieved through the drug’s direct binding to the alpha-adrenergic receptors on the blood vessel walls. By constricting these vessels, the drug effectively shrinks the swollen, engorged membranes that cause stuffiness. The general therapeutic purpose of Pernazene Oxy is, therefore, to provide temporary relief by opening up obstructed nasal passages and alleviating the sensation of pressure associated with congestion. The medicine is used to make breathing easier when the nasal passages are temporarily blocked, such as during a typical cold episode.

Regulatory References

  1. DrugBank, DB00989
  2. MedlinePlus Drug Information

What side effects are possible with Pernazene Oxy?

Safety Information and Adverse Reactions

Pernazene Oxy (Oxycodone) carries significant, life-threatening risks as formally defined by regulatory authorities, requiring a Boxed Warning and a Risk Evaluation and Mitigation Strategy (REMS).

Serious and Clinically Significant Adverse Reactions

The most serious risks include addiction, abuse, and misuse, which can lead to overdose and death. The most critical medical risk is life-threatening respiratory depression, which may occur at any time, especially upon initiation or following a dosage increase. Accidental ingestion, particularly by children, can result in a fatal overdose. Additional serious risks include Neonatal Opioid Withdrawal Syndrome (NOWS) with prolonged use during pregnancy, profound sedation or coma when used concomitantly with benzodiazepines or other Central Nervous System (CNS) depressants, and severe hypotension.

Common Side Effects

The most commonly reported adverse reactions (observed in >5% of patients) typically involve the gastrointestinal and nervous systems. These include constipation, nausea, somnolence (drowsiness), dizziness, vomiting, pruritus (itching), headache, dry mouth, asthenia (weakness), and sweating.

Safety Restrictions and Population Considerations

The drug is contraindicated in the presence of significant respiratory depression, acute or severe bronchial asthma, and known or suspected gastrointestinal obstruction (e.g., paralytic ileus). Particular caution and monitoring are required for elderly, cachectic (wasting), or debilitated patients due to an increased risk of respiratory depression. Patients with chronic pulmonary disease, head injury, or increased intracranial pressure are also at elevated risk. Interaction with CYP3A4 inhibitors or CNS depressants can significantly increase exposure and risk of fatal overdose. Dosage-related risk patterns confirm that the risk of overdose and death is increased because extended-release products deliver a larger amount of the opioid over an extended period.

Overdose and Emergency Response

Overdose and When to Seek Help

The following information summarizes the overdose profile for [Pernazene Oxy] as documented in authoritative regulatory sources (e.g., FDA, EMA).

Documented Overdose Presentations

Overdose with this product is primarily characterized by severe central nervous system (CNS) and respiratory depression. Documented signs include:

  • Respiratory Compromise: Slow, shallow, or labored breathing; severely decreased respiratory rate.
  • CNS Effects: Excessive drowsiness, progressing to stupor, or coma.
  • Systemic Signs: Pinpoint pupils (miosis), cold and clammy skin, muscle flaccidity, and slowed heart rate (bradycardia).

Life-Threatening Outcomes

Severe overdose can rapidly lead to life-threatening complications, including respiratory arrest, circulatory collapse, and potentially death. These severe outcomes are the basis for the requirement to seek immediate medical assistance.

When to Seek Immediate Medical Help

Urgent medical attention must be sought immediately if an overdose is suspected.

This is a non-negotiable instruction from official regulatory labeling, necessitated by the risk of fatal respiratory depression. Emergency services (e.g., 911 or equivalent) should be contacted immediately if an individual exhibits any of the following:

  • Extreme difficulty breathing or stopped breathing.
  • Inability to be roused or loss of consciousness.
  • Signs of circulatory failure or arrest.

Management and Monitoring

Official management involves the use of a specific opioid antagonist (such as naloxone) to reverse respiratory depression. Following antagonist administration, continuous monitoring is required due to the possibility of symptoms recurring.

Therapeutic Uses of Pernazene Oxy

The purpose of Pernazene Oxy is to offer symptomatic assistance across specific upper respiratory contexts, focusing exclusively on relief from congestion and associated discomfort. The medication is commonly used to provide supportive relief for nasal discomfort caused by conditions such as the common cold, various allergies, and hay fever.

It is generally applied in contexts where additional symptomatic support is needed for the nasal stuffiness and blockage that characterize these acute or episodic conditions. The medication is relevant for managing symptoms that interfere with daily comfort, including the feeling of fullness and tension associated with sinus pressure.

“The primary goal is providing supportive relief when symptoms interfere with routine activities, helping patients cope more steadily with symptom fluctuations.”

This supportive relief assists the patient during difficult episodes by easing distress and contributing to improved day-to-day comfort during symptomatic periods.


Quick Fact: Relief for Nasal Obstruction Pernazene Oxy is used for managing symptoms related to inflammatory or irritative states that result in acute blockage of the nasal passages.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility and Contraindications

Pernazene Oxy (oxycodone) is subject to strict eligibility rules based on governmental regulatory documents, restricting its use to certain populations and clinical situations.

Eligibility Status Population/Condition
Contraindicated Individuals with significant respiratory depression, acute or severe bronchial asthma in an unmonitored setting, known or suspected gastrointestinal obstruction (including paralytic ileus), or known hypersensitivity to oxycodone.
Use Restricted High-dose strengths (e.g., single doses > 40 mg) are reserved only for opioid-tolerant patients. Opioid tolerance is defined as receiving certain minimum daily opioid doses for at least one week.
Special Consideration Geriatric (older) patients, those with severe renal impairment (kidney disease), or hepatic impairment (liver disease) may require initial dose adjustments due to altered drug clearance.

Pediatric Eligibility: The medicine is generally not authorized for the general pediatric population. For some extended-release formulations, use is restricted to opioid-tolerant pediatric patients 11 years of age and older who meet specific, established minimum daily opioid requirements.

Pregnancy and Lactation: Use during pregnancy may result in fetal harm and is associated with the risk of Neonatal Opioid Withdrawal Syndrome (NOWS). Nursing mothers are generally not recommended to use the drug due to the risk of infant sedation and respiratory depression from drug excretion into breast milk.

These official rules strictly define who can and cannot use this medicine, primarily excluding those with critical respiratory or gastrointestinal compromise and those who lack established opioid tolerance for higher doses.

What should I know about interactions with other medicines?

The official regulatory profile for Pernazene Oxy (Oxymetazoline hydrochloride) defines interaction patterns that are classified across pharmacodynamic and pharmacokinetic domains. These restrictions are based on the drug's sympathomimetic activity and its local vasoconstrictive effect, as documented in government prescribing information.

Interaction Entity/Class Regulatory Status and Official Outcome
Monoamine Oxidase Inhibitors (MAOIs) Combination is classified as contraindicated or strongly restricted by regulators. The documented outcome is a risk of severe Hypertension (Hypertensive Crisis). Use is restricted for a period of 14 days after stopping MAOI therapy.
Tricyclic Antidepressants (TCAs) Co-administration with TCAs is officially documented to increase the risk of Hypertension and Arrhythmias due to pharmacodynamic reinforcement.
Anti-hypertensive Drugs The therapeutic effects of Anti-hypertensive medicines like Beta-blockers and others may be antagonised (reduced efficacy) by the drug’s vasoconstrictive action.
Anti-parkinsonian drugs The official label documents a risk of additive cardiovascular toxicity when combined with medicines such as Bromocriptine.

The drug's local action necessitates specific administration-timing rules for certain other intranasal products. Pernazene Oxy is officially documented to slow the rate of absorption of co-administered nasal medicines. To manage this pharmacokinetic interference, a minimum 1-hour separation between administrations is a stated requirement in the official labeling for specific combinations.

Mechanism of Action

Oxymetazoline functions as a direct-acting sympathomimetic agent, activating alpha-1 (alpha1) and alpha-2 (alpha2) adrenergic receptors found on vascular smooth muscle cells of the nasal mucosa. This binding initiates a signaling cascade that causes an acute, localized increase in intracellular calcium ( Ca^2+), leading to the contraction of the smooth muscle.

The activation of the receptors causes the vascular smooth muscle to contract, resulting in rapid vasoconstriction (narrowing) of the nasal blood vessels. This local restriction of blood flow reduces the blood volume and hydrostatic pressure within the microvasculature. The physiological consequence is a reduction of tissue volume in the mucosal membranes, which results in a lower resistance within the nasal airway.

This mechanism is subject to a limitation inherent in sustained agonist use. Prolonged stimulation leads to receptor desensitization and down-regulation of the alpha-adrenoceptors. This mechanism constraint results in tachyphylaxis (decreased pharmacological response) and, in extreme cases, compromises the vasoconstrictive response, leading to a compensatory vascular dilation upon drug withdrawal.

Dosage and Administration Information

How to Use Pernazene Oxy

Pernazene Oxy, containing Oxymetazoline hydrochloride, is officially designated for intranasal (topical) application as a nasal solution, available in forms such as a spray or drops at the 0.05% concentration. The usage instructions are strictly defined, focusing on precise administration and duration limits.


Official Dosing and Administration Schedule

Usage Parameter Instruction (0.05% Solution)
Standard Dose (Adults 12 years) 2 or 3 sprays (or drops) into each nostril per application.
Frequency Administered not more often than every 10 to 12 hours.
Maximum Daily Use Do not exceed two doses in any 24-hour period.

Use-Context Constraints and Special Rules

Duration Limit: Pernazene Oxy is indicated for a maximum of 3 consecutive days (or up to 5-7 days in some regional labels). This short-term use constraint defines the official context of the drug's administration.

Pediatric Use: For children aged 6 to under 12 years, the same 0.05% dose may be used, but requires adult supervision. The 0.05% solution is generally restricted or contraindicated for children under 6 years of age.

Procedural Rules: The dispenser must be used only by one person to prevent infection spread. If a dose is missed, it should be administered as soon as possible, but double dosing is explicitly prohibited if it is near the time for the next scheduled application.

Recent Clinical Evidence

Research evidence / Overview of studies for Pernazene Oxy

Evidence for Use in Acute Nasal Congestion

Research examining Oxymetazoline, the active substance in Pernazene Oxy, primarily focuses on research exploring nasal stuffiness associated with conditions characterized by acute or episodic manifestations, such as the common cold or upper respiratory allergies. The foundation of this evidence is built upon short-term, placebo-controlled Randomized Controlled Trials (RCTs) and subsequent systematic reviews.

In these studies, researchers monitored how symptoms changed during periods of increased symptom activity. Outcomes related to physical discomfort were evaluated using patient-reported outcomes describing perceived discomfort, often on specialized scales where participants recorded the intensity of their nasal blockage. Additionally, studies monitored objective physiological measures by measuring changes in nasal airflow and the physical volume of the nasal passages using specialized equipment. Studies reported patterns observed during phases of heightened symptom activity, with findings typically focusing on measurements taken within the first several hours after application.

The research base for short-term use is extensive, reflecting the quantity of controlled trials that have explored symptom changes over defined time intervals. However, this evidence primarily contributes to understanding acute symptom patterns. Research provides insight into short-term changes, but the evidence remains limited regarding changes observed beyond a single acute episode or the duration of treatment generally recommended on product labels.


Studies on Extended Use and Complex Nasal Obstruction

The compound was primarily studied in research scenarios involving short-term, acute symptoms, but research has also explored this compound in more complex research scenarios. Studies conducted during periods of increased symptom activity have sometimes included follow-up periods exceeding the typical short-term duration to investigate the potential for reliance or rebound effects.

Research examined specific outcomes related to functional imbalance and patient-reported quality of life in populations with chronic nasal obstruction. Findings were mixed across studies, with some evidence suggesting patterns related to a potentially diminished response or a return of congestion being observed when the compound was studied for extended periods. This evidence contributes to understanding the broader research landscape related to prolonged use.


Research Gaps and What Remains Uncertain

Objective published data is limited for specific subgroups, with most evidence existing for adult populations. Data for very young children, pregnant individuals, and those with certain comorbid conditions remain insufficient. Furthermore, limited long-term information means that the full scope of outcomes associated with extended or repeated use are not well understood from the existing evidence. Comparative evidence with other nasal decongestant classes is also often lacking or limited to short-term studies.

Key Studies & References Oxymetazoline Hydrochloride Nasal Solution, USP: Regulatory Drug Label and Monograph Information

Frequently Asked Questions (FAQ)

Common questions about Pernazene Oxy (FAQ)

Q: What is Pernazene Oxy used for?

A: Pernazene Oxy is indicated for the treatment of mild to moderate acute pain in adults and adolescents aged 16 years and older. According to the official product information, it is used for short-term symptom relief.

Q: Can I take Pernazene Oxy if I have a history of stomach ulcers?

A: Regulatory documents state that Pernazene Oxy should not be used by individuals with a current or recent history of recurrent stomach (peptic) ulcers or bleeding. The official product information specifies that this risk is heightened in people with a history of recurrent gastrointestinal issues.

Q: Does Pernazene Oxy cause drowsiness or affect my ability to drive?

A: Studies and official information indicate that Pernazene Oxy may cause side effects such as dizziness, somnolence (sleepiness), or fatigue. Due to these possible effects, official recommendations mention that caution should be exercised when performing skilled tasks, such as driving or operating machinery.

Q: What should I do if I miss a dose of Pernazene Oxy?

A: The official regulatory guidelines instruct that if a dose of Pernazene Oxy is missed, the patient should skip that dose and take the next dose at the regular time. Regulatory information states that a double dose must not be taken to compensate for a forgotten one.

Q: How long can I use Pernazene Oxy for pain?

A: Pernazene Oxy is intended for short-term use only, according to official sources, and treatment duration should not exceed 5 days. Regulatory documents state that if pain persists or for continued use beyond this period, a healthcare professional should be consulted.

Q: Is Pernazene Oxy safe for use during pregnancy?

A: Official regulatory sources advise that Pernazene Oxy should not be used during the third trimester of pregnancy. Use during the first and second trimesters is also not recommended, and official sources caution against use unless the potential benefit justifies the potential risk, as determined by a healthcare provider.

Q: Can I drink alcohol while taking Pernazene Oxy?

A: According to the official product information, the consumption of alcohol is advised against while using Pernazene Oxy. Combining alcohol with this medicine can increase the risk of certain side effects, including bleeding in the stomach.

Q: Does Pernazene Oxy contain aspirin?

A: No, the active ingredients in Pernazene Oxy are not aspirin. Official regulatory information lists the active ingredients as ibuprofen and codeine phosphate hemihydrate, which are a non-steroidal anti-inflammatory drug and an opioid analgesic, respectively.

How should Pernazene Oxy be stored and disposed of?

Storage and Disposal Requirements

The storage and disposal of Pernazene Oxy (Oxymetazoline hydrochloride nasal solution) are governed by official regulatory requirements to ensure product stability and prevent accidental exposure.

Storage Conditions

Requirement Official Instruction
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Protection Protect from excessive heat and do not freeze the solution.
Container Keep the container tightly closed when not in use and do not use after the expiration date.
Child Safety The medication must be stored out of the sight and reach of children.

Disposal

Expired or unused medication should be disposed of promptly. The preferred method is through a drug take-back program or an authorized collection site. If no take-back option is available, the product should be mixed with an unpalatable substance (e.g., dirt) and placed in a sealed bag before being discarded in the household trash; the product must not be flushed down a toilet or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pernazene Oxy found in:

A-Z Index: